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ABSTRACT  
Introduction: Obtaining informed consent from acute ischemic stroke patients poses many 
challenges, especially in the context of a research setting. Specifically, consenting for alternative 
acute ischemic stroke treatments to the standard of care, Tissue Plasminogen Activator (tPA), 
can cause delays leading to increased time to reperfusion and worse outcomes. 
Objectives: We sought to investigate the experiences of researchers in existing active-control 
trials in acute ischemic stroke comparing investigational therapy to tPA in order to identify the 
approaches and challenges in obtaining informed consent in this unique patient population. 
Methods: Out of 401 articles evaluated, 14 trials met inclusion criteria of patients receiving IV 
tPA vs alternative treatment within 4.5 hours of onset of symptoms for acute ischemic stroke. 
Trial representatives were emailed by the study team with a request for a copy of their patient 
consent form, other documents related to informed consent, and to complete a survey concerning 
aspects of the consent process.  
Results:  Of the 6 trials conducted across 6 continents that completed the survey in its entirety, 2 
were ongoing, 4 were published between 2009 and 2016, and the median NIHSS for each 
published trial was at least an 8. All published trials in the sample stated that informed consent 
was obtained, but only half reported involvement of a research ethics committee. Although 3 
trials performed in Europe or Asia reported directly consenting 75-100% of enrolled patients, the 
median NIHSS for these trials represented a moderate stroke. Trials with 75-100% of patients 
directly consented had shorter  door to treatment (DTT) times than trials that directly consented 
less than 50% of enrolled patients. 5 trials allowed consent by proxy, but only 2 of those trials 
also required patient assent. 4 trials had translators available and translated consent documents, 
and these trials had longer DTT times. All trials relied on experienced providers or dedicated 
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research coordinators to obtain informed consent; however, only 2 of 6 trials mentioned specific 
training with regards to informed consent skills. 
Conclusions: The current informed consent process is not transparent and poses challenges to 
investigators in the USA directly comparing tPA to an alternative treatment. International 
differences in the standards of informed consent, such as deferred consent, may have allowed 
more patients with moderate strokes to provide direct consent after treatment administration 
without delaying DTT time. While targeted and innovative approaches for informed consent are 
needed to improve patient outcomes, we must balance protecting the autonomy of individuals 
whose willing involvement enables such pivotal discoveries. The stroke community must aim for 
efficiency, transparency, and inclusion of patients of diverse backgrounds in the informed 
consent process so that therapeutic advances are possible.  
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INTRODUCTION  
Although the purpose of medical research involving human subjects is to generate knowledge 
that will potentially benefit a target population, this purpose should not take precedence over the 
rights of the individual research subjects.(1) Informed consent is the process by which 
permission is granted for a medical intervention: each human subject is informed of the aims, 
methods, risks, potential benefits, alternative treatments, and other relevant aspects of the study. 
The process of informed consent becomes challenging when a study is designed to intervene in 
an urgent and time-sensitive setting, such as stroke.  
The prevalence of stroke in the United States of America (USA) in 2016 was 2.5%, which is 
projected to increase to 3.9% by 2030.(2,3) Given this increasing burden, a large effort has been 
made to improve upon current stroke treatments. Administration of IV Tissue Plasminogen 
Activator (tPA) within 4.5 hours and mechanical thrombectomy for  large vessel occlusions 
within 6 hours of symptoms onset are the standard of care for eligible patients according to the 
American Heart Association (AHA) guidelines for acute ischemic stroke with significant 
functional deficits.(4,5) Reperfusion therapies in acute stroke show a clear time-dependent effect, 
being more effective the earlier treatment is initiated or reperfusion is achieved.(6–8) Therefore, 
time constraints on informed consent make the consent process difficult and may pose  a barrier 
to examining new and potentially more beneficial therapies.(9–12) 
Studying an alternative to tPA involves randomizing patients to tPA vs. investigational therapy; 
however, the brief informed consent process for administering tPA under high level 
recommendation alone without the added time burden of a formal consent process for a non-
standard-of-care therapy has been reported to delay treatment.(13) In addition, patients with 
severe stroke symptoms may not have the capacity to consent for research, and thus require 
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consent by proxy (14), which has also been shown to delay treatment, especially when consensus 
is needed among multiple family members.(13,15)  Another source of delay could be elderly 
patients with cognitive impairment, a population that commonly suffers from stroke. Not only do 
cognitive impairments complicate determination of capacity, but elderly patients may present to 
the emergency room unaccompanied, making it difficult to ascertain if they have a surrogate 
decision maker.(16) Although there has been investigation of alternate methods such as targeted 
consent models to  reduce delays in treatment (17), ethical considerations involved in conducting 
clinical research in the urgent setting with respect to the process of obtaining informed consent 
have been an area of ongoing deliberation.(12) 
 
In this study, we investigate the experiences of researchers in existing active-control trials in 
acute ischemic stroke comparing investigational therapy to tPA in order to identify the 
approaches and challenges in obtaining informed consent in this unique patient population. To 
evaluate the impact of research study factors on patient care, we also collected information on 
door to treatment (DTT) times of both experimental and control arms of trials. This information 
can serve to not only identify potential barriers and ethical considerations of performing such 
studies, but also promote new approaches in the acute setting for a more efficient informed 
consent process that balances being patient centered with the need to develop new interventions.  
 
METHODS 
This research study was reviewed by the University of Michigan Institutional Review Board for 
Human Subjects Research and determined to be exempt under IRB #HUM00180410. 
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Literature Search 
Literature searches with the aid of a University of Michigan research librarian were performed 
using the following platforms: PubMed (https://pubmed.ncbi.nlm.nih.gov/; Bethesda MD US),  
clinicaltrials.gov (https://clinicaltrials.gov/; US National Library of Medicine), National Institute 
of Public Health Clinical Trials Search (https://rctportal.niph.go.jp/en/; Japan), Europe PMC 
(https://europepmc.org/; Europe), EU Clinical Trials Register 
(https://www.clinicaltrialsregister.eu/ctr-search/search; The Netherlands), the Australian New 
Zealand Clinical Trials Registry (https://www.anzctr.org.au/; Australia), and International 
Clinical Trials Registry Platform (apps.who.int/trialsearch/; World Heath Organization). Peer-
reviewed scientific articles published in English language were identified using the following 
search terms: “alteplase” OR “tPA” OR “Activase” and "ischemic stroke" OR "acute ischemic 
stroke". Publication dates were restricted to January 1991 through March 2020. The PubMed 
search was further filtered by selecting Clinical Trials and Humans. The Clinicaltrials.gov search 
was further filtered by excluding recruitment status listed as suspended, terminated, withdrawn, 
or unknown. The Australian New Zealand Clinical Trials Registry search was further filtered by 
selecting “interventional” trial type. Inclusion criteria for trials were studies of patients with 
acute ischemic stroke who would be eligible for IV tPA administration within 4.5 hours of 
symptom onset and comparison of IV tPA versus an alternative treatment. Exclusion criteria 
were trials where IV tPA was combined with an alternative treatment, or where an alternative 
treatment was compared to a placebo. Three authors assessed all trials independently for 
eligibility and subsequently collaborated to agree upon the final trials included. Of the 401 
articles uploaded to Rayyan (https://rayyan.qcri.org/; Doha, Qatar) for researcher review, 14 
trials met inclusion and exclusion criteria (Figure 1).(18–31) 
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Studies Contacted 
The corresponding author and trial coordinators listed on clinicaltrials.gov from each of the 14 
trials were emailed by the study team with a request for a copy of their patient consent form, 
other documents related to informed consent, and to complete a survey developed as described 
below. The email also included a reminder that participation is voluntary and that emails would 
be collected at their own discretion. Individuals receiving the survey were asked to share the 
survey with other members of their trial team who were knowledgeable about informed consent 
for the trial. The survey contained 24 questions pertaining to the informed consent process, 
including multiple choice, and free response questions (Supp 1).  43 representatives from the 14 
trials were contacted. 6 studies completed the survey in its entirety, 1 study (AcT) partially 
completed the survey and therefore results were excluded, and the remaining 7 studies did not 
respond after a third contact.(18–31) 
 
Survey Development 
An anonymous online survey developed using Qualtrics (SAP software company; Utah, USA) 
assessed how informed consent was obtained in a population that may have challenges with 
standard consent due to absence of capacity in the setting of acute stroke. Survey questions 
included demographic questions (year of result publication, location, participants, and median 
NIHSS of trial arms), multiple choice (yes/no/unknown) questions regarding specific aspects of 
the informed consent process, and free response questions concerning challenges trials may have 
faced. A draft of the survey was presented to an acknowledged collaborator, Dr. Lesli Skolarus, 
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where specific feedback was provided on content and format. The survey was then revised and 
distributed to the 43 contacts mentioned above.  
 
Statistical Analysis  
Informed consent documents from each trial were analyzed for presence or absence of informed 
consent elements (Table 1). If data was published on median DTT times and the survey 
respondents used estimates of DTT times, the published DTT times of the trials were used in the 
statistical analysis. Descriptive statistics were displayed for continuous variables as either mean 
± standard deviation or median (interquartile range) depending upon data distributions, and as 
frequency (percent) for categorical variables. Nonparametric methods (including Wilcoxon Rank 
Sums and the Kruskal-Wallis test) were used to evaluate factors potentially impacting DTT time. 
Statistical analyses were performed using R version 3.62 (r-project.org) and Excel (Microsoft 




Table 1 shows the demographic characteristics of the 6 included trials, 2 of which are ongoing, 
and 4 of which were published between 2009 and 2016. The trials were conducted collectively in 
6 continents and the number of participants in each trial ranged widely from 7 to 3,206 patients. 
All 4 published trials mentioned the term informed consent and two trials explicitly stated the 
involvement of an ethics committee in their published manuscript.(32,33)  
 
Patient Capacity  
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The median NIHSS score for each completed trial was at least 8, meaning most participants 
experienced a moderate stroke (Table 1). 5 trials allowed for consent to be obtained from a 
designated patient proxy if the patient was deemed to lack capacity (Figure 2). Of those 5 trials, 
2 required assent from the patient if the patient was consented by proxy and the other two trials 
did not require patient assent. Trials reporting direct consent (defined as not consent by proxy) of 
75% to 100% of their participants were associated non-significantly with shorter DTT times than 
trials reporting direct consent of 25% to 50% of patients for both the experimental and control 
arms with a trend towards significance (group = median[IQR]; 75% to 100% experimental = 
32[16-48], control = 34[17.5-50.5];  25% to 50% experimental = 117.5[65-170], control 
117.5[65-170]). However, 2 of the 6 trials did impose a time limit for when informed consent 
needed to take place (Table 1). When trials were asked to comment on challenges that arose 
during study protocol development, all comments referenced problems delineating specific 
exclusion or inclusion criteria (Table 2). Additionally, when asked about challenges related to 
obtaining consent, 3 out of the 5 comments mentioned difficulty with obtaining proxy consent.  
 
Logistics of Obtaining Informed Consent 
All trials allowed research attendings to obtain informed consent in the ED, but no trial allowed 
consent to be obtained by nurses, EMTs, undergraduate students, or residents other than a 
neurology resident (Figure 3). Although some trials allowed consent to take place in the hospital 
and in 1 case over the phone, no trial allowed for consent to be obtained in an ambulance or 
while at an outside hospital (OSH) prior to transfer. When asked to describe the required formal 
training received specific to the informed consent process, only 2 trials mentioned specific 
training with regards to informed consent skills and 1 trial did not require formal training.  
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Foreign Language  
The 6 trials took place in various continents and 4 out of the 6 trials made translators and 
translated consent documents available. Interestingly, trials that offered translated consent 
documents had longer DTT than trials that did not offer translated documents in both the control 
and the experimental arms (Figure 4). Similarly, trials that offered translation services had longer 
DTT than trials that did not in both the control and experimental arms.     
 
DISCUSSION 
Acute stroke treatment trials face unique challenges in obtaining informed consent due to the 
time-sensitive nature of acute stroke treatments and a patient population with neurologic deficits. 
The goal of our study was to characterize the approaches and barriers to obtaining informed 
consent in trials comparing the effectiveness of tPA with alternative treatment. To our 
knowledge, this study is the first to investigate the experiences of international stroke trial 
investigators related to obtaining informed consent.(34) Our findings highlight the many 
challenges of obtaining consent in the acute setting and suggest that more transparency in current 
informed consent processes and a willingness to innovate from traditional consent are needed to 
develop treatments that improve stroke outcomes.  
 
Informed consent is a mechanism for patients to exercise autonomy in trial enrollment, but 
patients and their surrogates also derive value from informed consent discussions.(35,36) As 
such, the manner of patient participation is intrinsically an ethical factor in trials without 
straightforward informed consent processes, such as trials of acute stroke or other emergency 
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treatments. Investigators surveyed from the AbESTT II trial indicated that obtaining informed 
consent produces unnecessary delays, but simultaneously felt an exemption for informed consent 
was inappropriate.(37) Thus, the implementation of informed consent presents a conflict between 
balancing patient-centric care with faster DTT times for superior outcomes, development of 
superior stroke therapies, and respect for patients as autonomous human beings.(6,37)  
 
Demographics of Trials 
The 6 trials included were conducted at major stroke institutions internationally, with 
representation from North America, Asia, Europe, Australia, and South America. Because of this 
variation in location, different institutional and cultural values may have influenced the methods 
and parameters used for obtaining informed consent, as evidenced in previous studies.(38) One 
such unique challenge was that a centralized IRB was not yet established before some trials took 
place (Table 2). Therefore, each participating trial center created an individual consent protocol 
to be approved by the home institution IRB, which decreased reproducibility of the informed 
consent process across trial sites. Another significant variation observed was the number of 
participants: trials ranged from 7 to 3206. It is likely that trials with larger cohorts faced more 
challenges, but these multi-center trials may have had the motivation and resources to implement 
more standardized approaches at multiple locations. Although the differences between the trials 
examined may be related to trial design, legal, institutional, and cultural effects, these trials 
overall provide evidence of the diverse landscape of informed consent. 
 
Reporting the Consent Process 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted October 18, 2020. ; https://doi.org/10.1101/2020.10.14.20212779doi: medRxiv preprint 
Information regarding how consent was obtained, consent forms, timing, and personnel involved 
across these trials was highly variable, and often could not be located publicly through protocol 
papers or within the published manuscripts. Interestingly, only half of the trials mentioned the 
involvement of a research ethics committee in their published results. Ethical oversight in the 
design of future studies, as is the case in the ongoing AcT QuICR trial, may be a useful approach 
to mitigate ethical dilemmas and oversee abbreviated methods of informed consent.(26,39) 1 of 
the 6 trials enrolled patients via a waiver of informed consent. None of the 14 trials made a copy 
of the informed consent document publicly available. Even after contacting trials for a copy of 
the informed consent document, only 2 provided forms for further examination. The absence of 
information highlights the need for research ethics involvement in trial design and greater 
transparency concerning informed consent in published manuscripts.  
 
Patient Capacity and Consent by Proxy 
Given that patients experiencing a stroke are a vulnerable population on the basis of the 
neurologic nature of the disease, understanding patient capacity is critical.  In this study, 3 of 6 
trials reported consenting patients directly for 75 to 100 % of participants, while only one trial 
reported consenting patients directly for less than 25% of participants (Figure 2). It remains 
important, however, to include cognitively impaired subjects to determine the generalizability of 
the proposed interventions.(40) NIHSS scores reported indicate most participants experienced a 
moderate stroke (Table 1). In the moderate NIHSS group, the ability to cognitively understand 
circumstances and make an informed decision varies widely.(41,42) This potentially discordant 
finding between reports that the majority of patients directly consented and had a “moderate” 
stroke could be due to alternate definitions of direct consent outside of the USA.(43) 4 of the 6 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted October 18, 2020. ; https://doi.org/10.1101/2020.10.14.20212779doi: medRxiv preprint 
trials in this study were conducted outside of the USA, where deferred consent is commonly 
practiced.(44,45) Deferred consent involves randomization of the patient into the protocol based 
on the discretion of the investigator, followed by informed consent during a later phase of care. 
In that case, investigators may have received assent from the stroke patient in the acute phase 
and formal written consent from the legally authorized representative. Given this information, 
there may have been a difference in interpretation of the survey question, where trial 
representatives responded with a focus on who was actually signing the consent form rather than 
who initially provided consent before treatment was administered (Supp 1). This may explain 
why although most patients experienced a moderate stroke, trials responded that over 75% of 
stroke patients were directly consented. Although deferred consent is one possible solution to 
ensure patients receive treatment in a timely manner and are appropriately aware of therapies, 
patient autonomy may become an issue: the investigator cannot take away the medications or 
treatment already provided, even if the patient were to later decline participation in the trial.  
 
While it is unclear how trials in this study determined capacity for consent, other trials have used 
aspects of the NIHSS score to assess capacity, including the sections regarding “level of 
consciousness”, “best gaze”, and “best language.”(15) More research needs to be conducted 
about ways to best assess capacity in moderate NIHSS patients to determine whether examining 
aspects of the NIHSS is sufficient to determine capacity.(46) When capacity is lacking, many 
stroke trials use consent by proxy rather than direct consent to enroll patients.(43) From an 
ethical perspective, there is concern as to whether surrogates are aligned with the wishes of 
patients in research trials.(47) To address this issue, patient assent can be required in addition to 
proxy consent, which was performed in some of the trials in this study.(35) Although surrogate 
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decision makers must make difficult choices, the research team should still involve the patient to 
their fullest extent by attempting to gain assent when patient capacity is determined to be 
lacking. 
 
Logistics of Obtaining Informed Consent 
Although communication techniques employed during the consent process between research 
staff and patients are vital for ethical and efficient obtainment of consent, only a subset of the 
trials indicated a dedicated training process specific to the trial (Table 2). All trials in this study 
sample relied on highly educated and experienced providers as well as dedicated research 
coordinators to obtain consent (Figure 3a). A dedicated training protocol for delivering informed 
consent can ensure a high standard of communication and create more time to discuss the trial 
with patients and families.(46,48) A third party involved in obtaining consent may also place less 
pressure to enroll.(48) 
 
In the trials studied, consent was obtained in a variety of settings; however, only one trial 
allowed consent to be obtained over the phone and no trials obtained consent upon patient 
transfer or in an ambulance. Obtaining consent over the phone in a prehospital setting has been 
performed in the FAST-MAG trial and provided more time for patients to consider consent as 
well as increased efficiency.(49) We suggest that consent in the pre-hospital setting should be 
considered for future trials. In addition, 3 out of 5 trials reported challenges obtaining consent by 
proxy, some of which may be mitigated by phone consent (Table 2). Phone consent is important 
when no proxy is available within the time window due to geographic constraints.(36,50) 
However, it can be challenging to reach patient families with distressing information and ask for 
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a decision when they are most vulnerable. Another solution to consider in the case of acute 
stroke trials may be a waiver of consent, known as an exception from informed consent (EFIC) 
in the USA, as delays in treatment due to the time it takes to achieve informed consent can lead 
to worse outcomes for patients.(51,52) 
 
Recent revisions to the Common Rule in the Federal Rules for the Protection of Human Subjects 
emphasize the responsibility of researchers to deliver information with concise and simple 
language during the consent process.(53–55) Consent forms in the USA now should emphasize 
key points for participation up front.(56) This is important because enrollment decisions in stroke 
trials can occur in a highly stressful environment that may increase cognitive load and diminish 
comprehension. A third of the trials reviewed implemented a time limit in which consent had to 
be obtained (Table 1). This approach may be appropriate in the acute setting to indicate the time 
sensitive nature of the process to research staff and to promote efficiency in the consent process. 
One trial made note of the decision to allow patients to provide verbal consent to initiate 
treatment followed by deferred written consent (Table 3). Interpersonal communication may be a 
more efficient means to obtain consent and produce better understanding in comparison to the 
medium of paper forms.(48,57) As such, verbal consent has previously been proposed as a 
function-based approach to informed consent.(58–60) Shortening the consent form is another 
consideration to reduce complexity, however, a longer consent form may be appropriate for 
proxy decision making.(35,61,62) Overall, a more targeted consent model may be preferable on 
an ethical basis due to the time sensitive nature of benefit to the patient and the potential to 
enhance patient understanding.(17) 
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Foreign Language 
Translators and translated consent documents may provide an avenue to greater patient diversity 
in stroke trials. Trials which included patients with potential language barriers requiring 
translators and translated consent documents demonstrated a trend towards increased door-to-
treatment time, suggesting that efficiency and efficacy may be impacted where such barriers 
exist (Figure 4). Efforts to increase the availability of rapid bedside interpretation services, such 
as with interpreter phones and professional translators, may help correct well-documented, 
ethnicity-based disparities in thrombolysis.(63,64) Additional barriers in the consent process may 
also exist for patients who speak foreign languages. Patients with limited English proficiency 
may have lower health literacy, availability of surrogate decision makers, or knowledge of 
concepts related to study design, such as randomization and clinical equipoise.(65,66) These 
additional barriers increase the need for rapid translation services and education at the bedside to 
ensure informed consent is achieved in a timely manner and to promote representation of a 
diverse patient population. 
 
Limitations 
The findings from this study are limited by the small sample of trials that met inclusion criteria. 
We also did not have responses from 8 of the 14 trials that met inclusion criteria and could not 
locate trial protocols or procedure manuals that outlined the informed consent procedures. We 
welcome any trial investigators or staff to complete our survey through this link 
http://bit.ly/strokeconsent or by contacting the corresponding author. 
 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted October 18, 2020. ; https://doi.org/10.1101/2020.10.14.20212779doi: medRxiv preprint 
Some of the trials were ongoing, and the respondents could not complete all data fields. In cases 
where the trial was conducted across multiple clinical sites, responses may not reflect site-
specific variation in how informed consent was obtained. Trials were additionally limited to 
studies listed in trial registries in English, thus excluding the pool of international studies which 
otherwise satisfied inclusion criteria. Besides informed consent, unreported clinical factors, such 
as blood pressure management, may also influence the DTT times in the included trials.(67)  
 
Finally, the informed consent process for stroke trials may change in the future due to altered 
interpretation of EFIC.(68) EFIC was drafted in 1996 and finalized in 2013, but has not been 
frequently implemented in stroke trials.(52,69) Standard of care trials, such as those examined in 
this study, are typically not candidates for the waiver because of the proven moderate efficacy of 
tPA.(17,69) Other countries have different regulations and models of consent not captured by 
this study. A new landscape for informed consent in the acute setting may be necessary to ensure 
medical care does not stagnate and that research can allow for the development of the next 
standard of care. 
 
CONCLUSIONS 
Time is most valuable for patients suffering from a stroke: the amount of brain function regained 
is directly proportional to the time it takes to administer treatment. It is critical that investigators 
respect this race against time. However, investigators are researching thrombolytic therapies that 
have the potential to improve the quality of life and provide great benefit to society. Given the 
regulatory burden and patient family stress, the current informed consent process in the USA 
does not allow for direct comparison to discover a replacement for tPA. This research cannot 
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progress unless the standards of informed consent change or waivers are permitted, but we must 
balance protecting the individuals whose willing involvement enables such pivotal discoveries. 
Therefore, we recommend a new era of informed consent in acute stroke trials with ethical 
oversight to develop a targeted approach to informed consent based on European and Asian 
models, where most patients are directly consented. We acknowledge that uniform standards of 
obtaining consent may not be applicable in all trials or scenarios, but future trials should be 
designed with an emphasis on communication with patients of diverse backgrounds, robust 
consent protocols, and transparency in the informed consent process. This new approach will 
pave the way for more streamlined and inclusive study of treatments in acute stroke. 
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TABLES  
 
Table 1. Demographic characteristics of the 6 trials that completed the survey, including the 
median National Institutes of Health Stroke Scale (NIHSS) score, door to treatment times (DTT), 
and informed consent discussion in the published results from the trial.  
 ENCHANTED noR-TEST 
2 
IV vs. IA 
tPA 
TNKS2B noR-TEST TPK 
Derivative 
Status of Trial Completed Ongoing Completed Completed Completed Ongoing 
Year of Result 
Publication 
2016 Ongoing 2009 2010 2017 Ongoing 










3206 Ongoing 7 112 1100 Ongoing 
Median NIHSS 
Score (IQR) 




170 10 180 65 34 43 
Experimental 
Arm Median DTT 
(min) 




Yes No Yes No No No 
Informed Consent 
Mentioned 




Yes Ongoing Yes Yes Yes Ongoing 
Statement of 
Ethics Approval 
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Table 2. Commentary provided when asked to describe the challenges encountered with study 
protocol development or in obtaining informed consent from patients.  
Challenges with Study Protocol 
Development 
Challenges in Obtaining Informed Consent 
We are allowed to include patients in the trial 
on the basis of their verbal consent. Written 
informed consent is obtained after treatment 
has been administered. The rationale behind 
this is to avoid delay of treatment because of 
written informed consent.  
It is in some situations difficult to obtain a 
verbal informed consent in acute stroke 
patients. After the acute phase, it may also be 
difficult for the patients to give their written 
informed consent. In our study, it was also be 
challenging to obtain written informed 
consent for study participation from 
patient/proxy if the patient suffers from a 
complication such as intracranial hemorrhage 
following treatment.  
Too numerous to count. This was prior to the 
era of central IRB's, so each participating 
institutions had their own IRB weighing in on 
the consent. While our consent was 
templated, each participating institution's 
approved consent form was reviewed by us to 
be sure it contained all elements required by 
our IRB and OHRP.  
Finding proxies for aphasic patients unable to 
consent for themselves was sometimes 
challenging. If no proxy available, the patient 
could not be enrolled.  
The study was performed strictly according to 
SOP for acute stroke. Information and 
randomized treatment were the only study 
specific changes. Ethical aspects of informed 
consent in patients with a brain lesion, even a 
small one, resulted in lengthy discussions.  
We informed the patient verbally, regardless 
of the patients state. We did not require an 
oral consent from the patient for the 
treatment. The patient (or proxy) was later 
asked for a written consent to use their data 
for research. 
Whether patients given endovascular therapy 
will exclude them from the study. 
The safety and efficacy about the study drug. 








All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted October 18, 2020. ; https://doi.org/10.1101/2020.10.14.20212779doi: medRxiv preprint 
Table 3. If a trial indicated that professionals obtaining informed consent were required to 
complete formal training specific to the informed consent process, free text space was given to 
describe the training process.  
Trial Name Description of Required Formal Training for Informed Consent  
ENCHANTED They needed training in the protocol and how to obtain informed consent, 
specifically related to dealing with equipment. The only people who were allowed to 
obtain consent were those who had training and listed on a research delegation log 
approved by the site principal investigator and the project coordinating team. 
noR-TEST 2 Not required.  
IV vs. IA tPA CITI training. 
TNKS2B Computerized learning modules plus face-to-face teaching. 
noR-TEST Training course for Local Investigators (LI) by the organizing center. LI providing 
training in the participating hospitals. 
TPK Derivative  Training about the guideline for thrombolysis for the acute ischemic stroke. Training 







All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted October 18, 2020. ; https://doi.org/10.1101/2020.10.14.20212779doi: medRxiv preprint 
FIGURES 
Figure 1. Flowchart of results from the literature search conducted.  
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Figure 2. Patients were either directly consented to the trial, consented by proxy with required 
assent from the patient, or consented by proxy without assent. A) Number of trials requiring 
assent in addition to consent by proxy. DTT of the B) control arm and C) experimental arm was 
plotted in relation to percentage of patients directly consented divided into quartiles: 0% to 25% 
(n=1), 25% to 50% (n=2), 50% to 75% (n=0), 75% to 100% (n=3).  
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Figure 3.  A) The types of professionals obtaining consent and B) the location consent was 
obtained. The Emergency Department (ED) was considered a separate location from the hospital 
itself. Outside hospital (OSH) was defined as a hospital other than where the study was being 
conducted. 
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Figure 4. The effect of translator services on the DTT for trials. The DTT for the A+C) control 
arm and B+D) experimental arm were plotted in relation to having A+B) translated consent 
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